UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2014 (September 26, 2014)

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (408) 530-1900

No change 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 26, 2014 (the “Grant Date”), the Compensation Committee of the Board of Directors of Viveve Medical, Inc. (the “Company”) granted Patricia Scheller, the Company’s Chief Executive Officer, and Scott Durbin, the Company’s Chief Financial Officer, 939,318 and 382,420 incentive stock options to purchase shares of the Company’s common stock, respectively (collectively, the “Options”), under the Company’s 2013 Stock Option and Incentive Plan (the “Plan”). The Options vest over a period of four years beginning on the Grant Date in increments of 1/48^th per month. The Options have an exercise price of $0.60 per share and expire on the ten year anniversary of the Grant Date.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.